ADC Therapeutics SA, of Lausanne, Switzerland, said it received clearance from the FDA to begin trials testing ADCT-402, an antibody-drug conjugate targeting CD19, which is overexpressed in many patients with B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL).